CRISPR Medicine News, 18 January 2021 | Porteus Interview on Graphite Bio SCD treatment - CRISPR Medicine

CRISPR QC pioneers streamlined and automated CRISPR quality control tools to accelerate research while improving accuracy and performance.


Porteus Interview on Graphite Bio CRISPR treatment of Sickle Cell Disease

The outstanding results from the first CRISPR gene editing therapy for haemoglobinopathies by Vertex Pharmaceuticals and CRISPR Therapeutics has only just landed when news of a second more direct approach arrived.
With a new IND in hand, Graphite Bio plans to begin clinical trials for a CRISPR treatment that will restore normal haemoglobin expression in Sickle Cell Disease patients. The news raises hope for millions of people worldwide, and we talk to gene editing pioneer, Dr. Matthew Porteus, Stanford University. He is both a co-founder of Graphite Bio and a scientific founder of CRISPR Therapeutics: There Are Now Two Pushes to Treat Sickle Cell Disease With CRISPR.

Career CRISPR Medicine

Thank you for now - more great reads are on the way!

And if you have questions or suggestions, you can reach out to us directly at We love hearing from readers!

Happy Reading!


p.s. You can follow CRISPR Medicine News on Twitter and LinkedIn. If someone forwarded this email to you, you can sign up for our newsletter yourself here.